Epizyme reported $186.84M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agios Pharmaceuticals AGIO:US USD 784.94M 85.07M
Amarin AMRN:US USD 686.52M 32.6M
Amgen AMGN:US USD 24.06B 4.74B
Avrobio Inc AVRO:US USD 126.23M 15.85M
Biogen BIIB:US USD 9.77B 24.9M
Bluebird Bio BLUE:US USD 160.44M 7.02M
Daiichi Sankyo 4568:JP JPY 1.46T 90.16B
Eisai 4523:JP JPY 585.38B 35.57B
Exelixis EXEL:US USD 1.84B 10.02M
Gilead Sciences GILD:US USD 13.9B 723M
GlaxoSmithKline GSK:LN GBP 20.25B 33.94B
Glaxosmithkline GSK:US GBP 20.25B 33.94B
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Macrogenics MGNX:US USD 147.81M 19.82M
Mirati Therapeutics MRTX:US USD 1.23B 22.86M
Novartis NOVN:VX USD 36.95B 1.19B
Novartis NVS:US USD 36.95B 1.19B
Regeneron Pharmaceuticals REGN:US USD 15.43B 101.3M
Seattle Genetics SGEN:US USD 2.76B 19.04M
Spectrum Pharmaceuticals SPPI:US USD 112.98M 39.4M
Vertex Pharmaceuticals VRTX:US USD 12.27B 767.5M
Xencor XNCR:US USD 668M 82.06M